Vical Incorporated (VICL) Release: Preclinical Data Support Potential Combinations for Allovectin® With Emerging Immunotherapies
11/8/2012 9:24:06 AM
SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the release of animal data at a melanoma conference documenting the benefits of combining the company's Allovectin® immunotherapy with anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, which are emerging immunotherapies for metastatic melanoma. The company also announced a new publication1 supporting Allovectin®'s proposed mechanisms of action.
comments powered by